Story perspectives

Neurocrine Acquires Soleno for $2.9 Billion, Expands Portfolio

4/6/2026

Summary

Story summary

Neurocrine Biosciences will acquire Soleno Therapeutics for $2.9 billion, expanding its portfolio.
The deal includes Soleno's FDA-approved drug Vykat XR, the first treatment for hyperphagia in Prader-Willi syndrome.
Neurocrine will pay $53 per share, a 34% premium, with closing expected within 90 days.
Vykat XR generated $190 million in sales in 2025 with strong early adoption.
Analysts see Vykat XR's blockbuster potential, though long-term prospects and market penetration remain uncertain.

History

Historical Context

In 1992, Neurocrine Biosciences was founded to develop treatments for neurological and endocrine disorders. The company gained attention in 2017 with the FDA approval of valbenazine for tardive dyskinesia. Its recent $2.9 billion acquisition of Soleno Therapeutics in 2023 underscores a trend of consolidation in the biotech industry, aiming to address unmet medical needs and reshape future drug development strategies.

1 of 2

Story summary

Neurocrine Biosciences will acquire Soleno Therapeutics for $2.9 billion, expanding its portfolio.
The deal includes Soleno's FDA-approved drug Vykat XR, the first treatment for hyperphagia in Prader-Willi syndrome.
Neurocrine will pay $53 per share, a 34% premium, with closing expected within 90 days.
Vykat XR generated $190 million in sales in 2025 with strong early adoption.
Analysts see Vykat XR's blockbuster potential, though long-term prospects and market penetration remain uncertain.

1 / 2